Cancer Family
Urinary System Neoplasm
CI-CAN-00000379Explore in graph →
Non-malignant965 active trials28 approved drugs109 evidence items
- NCIt
- C3431
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000379Explore in graph →
Clinical trials
4,240 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01505569 | Auto Transplant for High Risk or Relapsed Solid or CNS Tumors | completed | N/A | 44 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Feb 26, 2024 | clinicaltrials |
| NCT02944617 | Probiotic Yogurt Supplement in Reducing Diarrhea in Patients With Metastatic Kidney Cancer Being Treated With Vascular Endothelial Growth Factor-Tyrosine Kinase Inhibitor | completed | N/A | 21 | City of Hope Medical CenterOTHER | 1 | Feb 23, 2024 |
| clinicaltrials |
| NCT03788746 | Prevalence of PD-L1 Expression in Patients With Advanced Urothelial Carcinoma(PREVAIL) | completed | — | 181 | AstraZenecaINDUSTRY | 1 | Feb 22, 2024 | clinicaltrials |
| NCT03892642 | Avelumab Plus Bacille Calmette-Guerin (BCG) in Patients With Non-muscle Invasive Bladder Cancer(OU-SCC-ABC) | completed | Phase 1 / Phase 2 | 18 | University of OklahomaOTHER | 1 | Feb 14, 2024 | clinicaltrials |
| NCT06235853 | Biomarkers of Recurrence and Progression in Non-muscle Invasive Bladder Cancer | completed | — | 240 | Wroclaw Medical UniversityOTHER | 1 | Feb 1, 2024 | clinicaltrials |
| NCT03962933 | Urine-based Detection of Non-muscle Invasive Bladder(SOLUSION) | completed | — | 196 | Nessn AzawiOTHER | 1 | Jan 30, 2024 | clinicaltrials |
| NCT03511391 | CHEckpoint Inhibition in Combination With an Immunoboost of External Beam Radiotherapy in Solid Tumors(CHEERS) | completed | Phase 2 | 99 | University Hospital, GhentOTHER | 1 | Jan 23, 2024 | clinicaltrials |
| NCT06205277 | Predictors of Residual Tumor at Second Transurethral Resection for pT1 Non-muscle Invasive Bladder Cancer(START) | completed | — | 1,300 | University of TriesteOTHER | 1 | Jan 12, 2024 | clinicaltrials |
| NCT06193941 | Research on the Accurate Diagnosis of Urinary Tract Tumors and the Development of Kits | completed | — | 400 | Zhongnan HospitalOTHER | 1 | Jan 9, 2024 | clinicaltrials |
| NCT04496219 | Acupuncture for the Treatment of Intravesical BCG-Related Adverse Events in High-Risk Non-muscle Invasive Bladder Cancer | completed | Phase 2 | 45 | Fred Hutchinson Cancer CenterOTHER | 1 | Jan 2, 2024 | clinicaltrials |
| NCT03454451 | CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers | completed | Phase 1 | 117 | Corvus Pharmaceuticals, Inc.INDUSTRY | 2 | Dec 21, 2023 | clinicaltrials |
| NCT02482168 | Study of the CD40 Agonistic Monoclonal Antibody APX005M | completed | Phase 1 | 43 | Apexigen America, Inc.INDUSTRY | 1 | Dec 20, 2023 | clinicaltrials |
| NCT04073602 | A Study of RC48-ADC in Subjects With HER2-negative Locally Advanced or Metastatic Urothelial Cancer | completed | Phase 2 | 19 | RemeGen Co., Ltd.INDUSTRY | 1 | Dec 18, 2023 | clinicaltrials |
| NCT06169904 | B7-Family Score in Urothelial Carcinoma | completed | — | 215 | Shanghai Zhongshan HospitalOTHER | 0 | Dec 14, 2023 | clinicaltrials |
| NCT04535921 | Fear of Cancer Recurrence in Genitourinary Cancer | completed | — | 500 | Ludwig-Maximilians - University of MunichOTHER | 1 | Dec 11, 2023 | clinicaltrials |
| NCT05861778 | Evaluation of 89Zr-TLX250 PET/CT in Chinese Patients With Indeterminate Renal Masses or Suspected Recurrent Renal Clear Cell Carcinoma(ZIRDOSE-CP) | completed | Phase 1 | 10 | Telix Pharmaceuticals (Innovations) Pty LimitedINDUSTRY | 1 | Dec 11, 2023 | clinicaltrials |
| NCT02676180 | Detecting Bladder Cancer Using the UroMark Test.(DETECT I) | completed | — | 3,700 | University College, LondonOTHER | 1 | Dec 8, 2023 | clinicaltrials |
| NCT02030067 | Dose-Finding and Safety Study for Oral Single-Agent to Treat Advanced Malignancies | completed | Phase 1 / Phase 2 | 127 | Processa PharmaceuticalsINDUSTRY | 1 | Dec 6, 2023 | clinicaltrials |
| NCT03229278 | Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma | completed | Phase 1 | 14 | Rutgers, The State University of New JerseyOTHER | 1 | Dec 6, 2023 | clinicaltrials |
| NCT02795156 | Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations | completed | Phase 2 | 100 | SCRI Development Innovations, LLCOTHER | 1 | Dec 5, 2023 | clinicaltrials |
| NCT06156787 | Patterns of Urinary Bladder Cancer in Darfur, Suda | completed | — | 105 | National Center for Gastroentestinal and Liver DiseaseOTHER | 1 | Dec 5, 2023 | clinicaltrials |
| NCT02781428 | To Detect the Sensitivity of the UroMark Assay(DETECT II) | completed | — | 1,643 | University College, LondonOTHER | 1 | Dec 4, 2023 | clinicaltrials |
| NCT00606866 | MRI Study of BAY 43-9006 in Metastatic Renal Cell Carcinoma(MRI) | completed | Phase 3 | 57 | University of ChicagoOTHER | 1 | Nov 29, 2023 | clinicaltrials |
| NCT03809013 | A Open-label, Single-arm, Multicenter, Phase II Study of RC48-ADC to Evaluate the Efficacy and Safety of Subjects With HER2 Overexpressing Locally Advanced or Metastatic Urothelial Cancer | completed | Phase 2 | 64 | RemeGen Co., Ltd.INDUSTRY | 1 | Nov 27, 2023 | clinicaltrials |
| NCT02599324 | Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors | completed | Phase 1 / Phase 2 | 263 | Pharmacyclics LLC.INDUSTRY | 4 | Nov 18, 2023 | clinicaltrials |
| NCT02527434 | Study of Tremelimumab in Patients With Advanced Solid Tumors | completed | Phase 2 | 64 | AstraZenecaINDUSTRY | 5 | Nov 15, 2023 | clinicaltrials |
| NCT02498665 | A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies | completed | Phase 1 | 24 | Sumitomo Pharma America, Inc.INDUSTRY | 1 | Nov 14, 2023 | clinicaltrials |
| NCT05154084 | RESECT: Improving Quality in TURBT Surgery.(RESECT) | completed | — | 19,505 | British Urology Researchers in Surgical TrainingOTHER | 1 | Nov 14, 2023 | clinicaltrials |
| NCT04021238 | Contrast-Enhanced Ultrasound for Kidney Cancer Subtyping and Staging | completed | Phase 2 | 25 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Nov 13, 2023 | clinicaltrials |
| NCT06111560 | Exploring the Influence of Clinical Factors on the Prognosis of Papillary Renal Cell Carcinoma | completed | — | 160 | Sun Yat-sen UniversityOTHER | 0 | Nov 1, 2023 | clinicaltrials |
| NCT04045613 | Derazantinib and Atezolizumab in Patients With Urothelial Cancer(FIDES-02) | completed | Phase 1 / Phase 2 | 95 | Basilea PharmaceuticaINDUSTRY | 14 | Oct 13, 2023 | clinicaltrials |
| NCT03998579 | Physical Rehabilitation Among Patients Undergoing Radical Cystectomy Due to Urinary Bladder Cancer(CanMoRe) | completed | N/A | 100 | Karolinska InstitutetOTHER | 1 | Oct 11, 2023 | clinicaltrials |
| NCT00617799 | Biomarkers That Predict Response to High-Dose Aldesleukin in Metastatic Kidney Cancer or Metastatic Melanoma | completed | — | 15 | University of NebraskaOTHER | 1 | Oct 10, 2023 | clinicaltrials |
| NCT02897375 | Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors | completed | Phase 1 | 71 | Emory UniversityOTHER | 1 | Oct 10, 2023 | clinicaltrials |
| NCT04534309 | Behavioral Weight Loss Program for Cancer Survivors in Maryland(ASPIRE) | completed | N/A | 340 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Oct 10, 2023 | clinicaltrials |
| NCT00003102 | Monoclonal Antibody Therapy in Treating Patients With Advanced Kidney Cancer | completed | Phase 1 / Phase 2 | 15 | Ludwig Institute for Cancer ResearchOTHER | 1 | Oct 4, 2023 | clinicaltrials |
| NCT03680521 | Neoadjuvant Sitravatinib in Combination With Nivolumab in Patients With Clear Cell Renal Cell Carcinoma | completed | Phase 2 | 25 | Mirati Therapeutics Inc.INDUSTRY | 1 | Oct 4, 2023 | clinicaltrials |
| NCT02643043 | UC-GENOME: Urothelial Cancer-GENOmic Analysis to iMprove Patient Outcomes and rEsearch | completed | N/A | 219 | Matthew Milowsky, MDOTHER | 1 | Sep 29, 2023 | clinicaltrials |
| NCT06055660 | Moesin Expression in Clear Cell Renal Cell Carcinoma | completed | — | 50 | Sohag UniversityOTHER | 0 | Sep 28, 2023 | clinicaltrials |
| NCT01517243 | Phase II Study of Alternating Sunitinib and Temsirolimus | completed | Phase 2 | 37 | Dartmouth-Hitchcock Medical CenterOTHER | 1 | Sep 21, 2023 | clinicaltrials |
| NCT02386826 | INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme | completed | Phase 1 | 65 | SCRI Development Innovations, LLCOTHER | 1 | Sep 21, 2023 | clinicaltrials |
| NCT04994639 | Hypotension Prediction Effect on AKI | completed | N/A | 120 | Ewha Womans University Mokdong HospitalOTHER | 1 | Sep 21, 2023 | clinicaltrials |
| NCT02722538 | Safety and Tolerability of GemRIS 225 mg in Subjects With Muscle-Invasive Bladder Cancer | completed | Phase 1 | 23 | Taris Biomedical LLCINDUSTRY | 2 | Sep 18, 2023 | clinicaltrials |
| NCT03207347 | A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001) | completed | Phase 2 | 37 | University of FloridaOTHER | 1 | Sep 15, 2023 | clinicaltrials |
| NCT03639714 | A Study of a Personalized Neoantigen Cancer Vaccine | completed | Phase 1 / Phase 2 | 29 | Gritstone bio, Inc.INDUSTRY | 2 | Sep 13, 2023 | clinicaltrials |
| NCT04475029 | Methadone in Cystectomy Patients(METAMORF) | completed | N/A | 114 | University of AarhusOTHER | 1 | Sep 13, 2023 | clinicaltrials |
| NCT06020807 | Analytical Specificity of Bladder EpiCheck Test in Healthy Population and Urology Patients Without Prior History or Evidence of Bladder Cancer | completed | — | 168 | Nucleix Ltd.INDUSTRY | 1 | Sep 7, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Feb 26, 2024source: clinicaltrials